The Middle East and Asia Pacific Antibody Drugs Market, by Type (Monoclonal Antibodies, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, and Anti-idiotype Antibody), by Disease Indication (Oncology, Neurology, Autoimmune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Middle East (Kingdom of Saudi Arabia, UAE, Israel, Iran, Jordan, Turkey, Qatar, and Rest of Middle East) and Asia Pacific (South East Asia, The Philippines, Malaysia, Singapore, Thailand, Vietnam, Rest of South East Asia, Taiwan, Hong Kong, Macau, Japan, South Korea, India, Australia, China, and Rest of Asia Pacific)) is estimated to be valued at US$ 43,558.2 Million in 2022 and is expected to exhibit a CAGR of 12.7% during the forecast period (2022-2030).
Increasing research and development activities in the field of antibody drug production is expected to drive the Middle East and Asia Pacific antibody drugs market growth over the forecast period. For instance, according to a review article published by the Asian Pacific Journal of Allergy and Immunology in March 2020, the therapeutic potential of monoclonal antibodies in treating diseases such as cancer, autoimmune disorders, and others has been well known to the researchers. Thus, researchers are actively involved in carrying out intensive research in the field of monoclonal antibodies against SARSCOV, which can also be used for the treatment of the COVID-19 infection due to their genetic similarities.
Middle East and Asia Pacific Antibody Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has affected various industries globally. Key players operating in the Middle East and Asia Pacific antibody drugs market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19), Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of February 22, 2022, is approximately 424,822,073 confirmed cases with 5,890,312 deaths.
However, the COVID-19 pandemic is expected to have a positive impact on the Middle East and Asia Pacific antibody drugs market, owing to rapid research for the development of antibody drugs that can be used for the treatment of the COVID-19. For instance, in November 2021, the Department of Health, Abu Dhabi entered into a collaboration with F. Hoffmann-La Roche Ltd, a Switzerland-based pharmaceutical company to make Regen-Cov (manufactured by F. Hoffmann-La Roche Ltd) available in Abu Dhabi. Regen-Cov is a drug therapy which is a combination of two monoclonal antibodies: casirivimab and imdevimab. Regen-Cov can be used for the treatment of COVID-19 patients as well as to protect non-patients from the COVID-19 infection.
Browse 88 Market Data Tables and 47 Figures spread through 242 Pages and in-depth TOC on “Middle East and Asia Pacific Antibody Drugs Market”- Forecast to 2030, Middle East and Asia Pacific Antibody Drugs Market, by Type (Monoclonal Antibodies, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, and Anti-idiotype Antibody), by Disease Indication (Oncology, Neurology, Autoimmune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Middle East (Kingdom of Saudi Arabia, UAE, Israel, Iran, Jordan, Turkey, Qatar, and Rest of Middle East) and Asia Pacific (South East Asia, The Philippines, Malaysia, Singapore, Thailand, Vietnam, Rest of South East Asia, Taiwan, Hong Kong, Macau, Japan, South Korea, India, Australia, China, and Rest of Asia Pacific)) – Forecast 2030
To know the latest trends and insights prevalent in this market, click the link below:
The key players operating in the market are focusing on increasing the launches of new products /antibodies, which is expected to drive the growth of the Middle East and Asia Pacific antibody drugs market over the forecast period. For instance, in May 2021, Zydus Cadila, an Indian biopharmaceutical company, launched Trastuzumab Emtansine, the first Antibody Drugs Conjugate (ADC) biosimilar and a highly effective drug for the treatment of both Early and Advanced Human Epidermal Growth Factor Receptor 2 (HER2) positive Breast Cancer, under the brand name Ujvira.
Key Takeaways of the Middle East and Asia Pacific Antibody Drugs Market:
- The Middle East and Asia Pacific antibody drugs market is expected to exhibit a CAGR of 12.7% during the forecast period, owing to the increasing prevalence of cancer. For instance, according to the data published in the Chinese Medical Journal in April 2021, China accounted for 24% of newly diagnosed cases of cancer and 30% of cancer-related deaths worldwide in 2020.
- Among type, the monoclonal antibody segment is expected to dominate the market during the forecast period, owing to increasing regulatory approvals for monoclonal antibody drugs for the treatment of various diseases. For instance, in May 2021, The UAE’s Health & Prevention Ministry had approved the emergency use of GlaxoSmithKline (a British multinational pharmaceutical company) and Vir Biotechnology’s (a commercial-stage immunology company) Sotrovimab (Vir-7831), a monoclonal antibody for the treatment of the COVID-19.
- Among disease indication, the Oncology segment is expected to offer lucrative growth to the market during the forecast period, owing to the increasing regulatory approvals of antibody drugs for cancer treatment. For instance, in September 2021, Gilead Sciences, Inc. a research-based biopharmaceutical company, announced that Trodelvy (sacituzumab govitecan-hziy) has been approved by Health Canada for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have undergone two or more prior therapies, at least one of which was for metastatic illness.
- Major players operating in the Middle East and Asia Pacific antibody drugs market include Novartis AG, Amgen, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Johnson & Johnson Private Limited, AbbVie, Eli Lilly and Company, GlaxoSmithKline plc., Daiichi Sankyo Company, Limited, Celltrion Healthcare Co., Ltd., Mylan N.V., Boehringer Ingelheim International GmbH., Biocon, and Merck & Co., Inc.
